Enanta Pharmaceuticals (ENTA) Operating Expenses (2012 - 2026)

Enanta Pharmaceuticals (ENTA) has 15 years of Operating Expenses data on file, last reported at $29.0 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses fell 26.47% year-over-year to $29.0 million; the trailing twelve-month figure through Mar 2026 stood at $129.6 million (down 22.2% YoY), and the FY2025 full-year result was $150.7 million, down 20.42% from the prior year.
• Operating Expenses for Q1 2026 stood at $29.0 million, down from $29.9 million in the prior quarter.
• Across five years, Operating Expenses topped out at $57.2 million in Q1 2023 and bottomed at $29.0 million in Q1 2026.
• The 5-year median for Operating Expenses is $47.4 million (2022), against an average of $45.1 million.
• The widest annual swing landed in 2023, when Operating Expenses advanced 8.91%; it then declined 26.47% in 2026.
• A 5-year view of Operating Expenses shows it stood at $53.6 million in 2022, then retreated by 1.32% to $52.9 million in 2023, then decreased by 23.42% to $40.5 million in 2024, then declined by 26.26% to $29.9 million in 2025, then fell by 2.87% to $29.0 million in 2026.
• The last three Operating Expenses figures came in at $29.0 million (Q1 2026), $29.9 million (Q4 2025), and $33.5 million (Q3 2025), per Business Quant data.

Peer Comparison